Weiran Chai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Weiran Chai has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Haiyan Guo
Shanghai Jiao Tong University School of Medicine, Shanghai Ninth People’s Hospital, Shanghai, China
3 shared publicationsChuning Yang
Shanghai Jiao Tong University School of Medicine, Shanghai Ninth People’s Hospital, Shanghai, China
2 shared publicationsGuangen Feng
Department of Assisted Reproduction, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publicationsJiaying Lin
Shanghai Jiao Tong University School of Medicine, Shanghai Ninth People’s Hospital, Shanghai, China
2 shared publications- Jie Zhang
Department of Assisted Reproduction, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publications Mengjie Wei
Department of Assisted Reproduction, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publications
Latest Publications
- Open Access
- 18 February 2026
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 19 (1) , 65
Correction: A prospective cohort study on progestin-primed ovarian stimulation vs. GnRH antagonist in IVF-ICSI cycles: effects on clinical pregnancy and neonatal outcomes
- 18 February 2026
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 19 (1) , 65
Open AccessCorrection: A prospective cohort study on progestin-primed ovarian stimulation vs. GnRH antagonist in IVF-ICSI cycles: effects on clinical pregnancy and neonatal outcomes
- Open Access
- 27 November 2025
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 18 (1)
A prospective cohort study on progestin-primed ovarian stimulation vs. GnRH antagonist in IVF-ICSI cycles: effects on clinical pregnancy and neonatal outcomes
In assisted reproductive technology, preventing premature ovulation is crucial for achieving successful pregnancy outcomes. The traditional GnRH antagonist
- 27 November 2025
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 18 (1)
Open AccessA prospective cohort study on progestin-primed ovarian stimulation vs. GnRH antagonist in IVF-ICSI cycles: effects on clinical pregnancy and neonatal outcomes
In assisted reproductive technology, preventing premature ovulation is crucial for achieving successful pregnancy outcomes. The traditional GnRH antagonist
- Open Access
- 14 September 2022
- Published by Elsevier in AJOG Global Reports
- Vol. 3 (1) , 100098
Association of infertility cause with perinatal outcomes in a freeze-all policy: an analysis including 10,151 singleton newborns
- 14 September 2022
- Published by Elsevier in AJOG Global Reports
- Vol. 3 (1) , 100098
Open AccessAssociation of infertility cause with perinatal outcomes in a freeze-all policy: an analysis including 10,151 singleton newborns
- 30 July 2022
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 45 (6) , 1266-1273
The impact of a previous tubal ectopic pregnancy on live birth and perinatal outcomes in vitrified-warmed cycles
- 30 July 2022
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 45 (6) , 1266-1273
The impact of a previous tubal ectopic pregnancy on live birth and perinatal outcomes in vitrified-warmed cycles
- Open Access
- 13 June 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (12) , 3386
Differences in Ectopic Pregnancy Rates between Fresh and Frozen Embryo Transfer after In Vitro Fertilization: A Large Retrospective Study
Ectopic pregnancy (EP) is increasingly found in women treated with in vitro fertilization and embryo transfer (IVF–ET). With the development of the freeze-all policy in reproductive medicine, it is controversial whether frozen embryo transfer (FET) could reduce the rate of EP. In this single-center, large-sample retrospective study, we analyzed 16,048 human chorionic gonadotrophin (hCG)-positive patients who underwent fresh embryo transfer (ET) or FET cycles between January 2013 and March 2022. Throughout the study, the total EP rate was 2.09% (336/16,048), 2.16% (82/3803) in the ET group, and 2.07% (254/12,245) in the FET group. After adjustment for age, infertility causes, and other confounding factors, logistic regression results showed no statistical difference in EP rates between FET and ET groups (odds ratio (OR) 0.93 (0.71–1.22), p > 0.05). However, among the 3808 patients who underwent fresh ET cycles, the OR for EP was significantly lower in the long agonist protocol group than in the gonadotropin-releasing hormone antagonist (GnRH-ant) protocol group (OR 0.45 (0.22–0.93), p < 0.05). Through a large retrospective study, we demonstrated a slightly lower EP rate in FET cycles than in fresh ET cycles, but there was no significant difference. The long agonist protocol in ET cycles had a significantly lower risk of EP than the GnRH-ant protocol.
- 13 June 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (12) , 3386
Open AccessDifferences in Ectopic Pregnancy Rates between Fresh and Frozen Embryo Transfer after In Vitro Fertilization: A Large Retrospective Study
Ectopic pregnancy (EP) is increasingly found in women treated with in vitro fertilization and embryo transfer (IVF–ET). With the development of the freeze-all policy in reproductive medicine, it is controversial whether frozen embryo transfer (FET) could reduce the rate of EP. In this single-center, large-sample retrospective study, we analyzed 16,048 human chorionic gonadotrophin (hCG)-positive patients who underwent fresh embryo transfer (ET) or FET cycles between January 2013 and March 2022. Throughout the study, the total EP rate was 2.09% (336/16,048), 2.16% (82/3803) in the ET group, and 2.07% (254/12,245) in the FET group. After adjustment for age, infertility causes, and other confounding factors, logistic regression results showed no statistical difference in EP rates between FET and ET groups (odds ratio (OR) 0.93 (0.71–1.22), p > 0.05). However, among the 3808 patients who underwent fresh ET cycles, the OR for EP was significantly lower in the long agonist protocol group than in the gonadotropin-releasing hormone antagonist (GnRH-ant) protocol group (OR 0.45 (0.22–0.93), p < 0.05). Through a large retrospective study, we demonstrated a slightly lower EP rate in FET cycles than in fresh ET cycles, but there was no significant difference. The long agonist protocol in ET cycles had a significantly lower risk of EP than the GnRH-ant protocol.
- Open Access
- 1 March 2020
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 8 (6) , 377
Impacts of medroxyprogesterone acetate on oocytes and embryos: matched case-control study in women with stage III–IV ovarian endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization
Background: This study investigated the effects of medroxyprogesterone acetate (MPA) on the oocytes and embryos in patients with advanced endometriosis who had a normal ovarian reserve and tubal infertility and received controlled ovarian hyperstimulation (COH) and explored the characteristics and pregnancy outcomes in subsequent frozen-thawed embryo transfer (FET) cycles. Methods: In this prospective controlled study, 150 advanced endometriosis patients involving 150 in vitro fertilisation/intracytoplasmic sperm injection (IVF/ICSI) cycles and 163 FET cycles and 150 age-matched tubal infertility patients requiring 150 IVF/ICSI cycles and 115 FET cycles were recruited. Patients with endometriosis were sub-grouped into surgery group (n=102) (they were diagnosed with ovarian endometriomas and underwent 102 IVF/ICSI and 115FET cycles) and aspiration group (n=48) [they had ovarian “chocolate” cysts (>3 cm) that were aspirated and underwent 48 IVF/ICSI and 74 FET cycles]. Results: Lower oocyte retrieval rate was noted in the endometriosis group than in the control group. Similar oocyte yield and peak estrogen (E2) level were found in two groups. The rates of mature oocyte, fertilization, cleavage, high-quality embryo, viable embryo, cancellation, implantation, and clinical pregnancy were similar between two groups. A higher oocyte yield was observed in the EMS cyst group than in the surgery group. Conclusions: The ovary response, oocytes, embryos and pregnancy outcome were not influenced by the advanced endometriosis and the use of MPA and also independent of endometrioma or cyst surgery.
- 1 March 2020
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 8 (6) , 377
Open AccessImpacts of medroxyprogesterone acetate on oocytes and embryos: matched case-control study in women with stage III–IV ovarian endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization
Background: This study investigated the effects of medroxyprogesterone acetate (MPA) on the oocytes and embryos in patients with advanced endometriosis who had a normal ovarian reserve and tubal infertility and received controlled ovarian hyperstimulation (COH) and explored the characteristics and pregnancy outcomes in subsequent frozen-thawed embryo transfer (FET) cycles. Methods: In this prospective controlled study, 150 advanced endometriosis patients involving 150 in vitro fertilisation/intracytoplasmic sperm injection (IVF/ICSI) cycles and 163 FET cycles and 150 age-matched tubal infertility patients requiring 150 IVF/ICSI cycles and 115 FET cycles were recruited. Patients with endometriosis were sub-grouped into surgery group (n=102) (they were diagnosed with ovarian endometriomas and underwent 102 IVF/ICSI and 115FET cycles) and aspiration group (n=48) [they had ovarian “chocolate” cysts (>3 cm) that were aspirated and underwent 48 IVF/ICSI and 74 FET cycles]. Results: Lower oocyte retrieval rate was noted in the endometriosis group than in the control group. Similar oocyte yield and peak estrogen (E2) level were found in two groups. The rates of mature oocyte, fertilization, cleavage, high-quality embryo, viable embryo, cancellation, implantation, and clinical pregnancy were similar between two groups. A higher oocyte yield was observed in the EMS cyst group than in the surgery group. Conclusions: The ovary response, oocytes, embryos and pregnancy outcome were not influenced by the advanced endometriosis and the use of MPA and also independent of endometrioma or cyst surgery.
- Open Access
- 12 June 2008
- Published by Springer Nature in BMC Cell Biology
- Vol. 9 (1) , 31
Mechanism of nuclear factor of activated T-cells mediated FasL expression in corticosterone -treated mouse Leydig tumor cells
Background: Fas and FasL is important mediators of apoptosis. We have previously reported that the stress levels of corticosterone (CORT, glucocorticoid in rat) increase expression of Fas/FasL and activate Fas/FasL signal pathway in rat Leydig cells, which consequently leads to apoptosis. Moreover, our another study showed that nuclear factor of activated T-cells (NFAT) may play a potential role in up-regulation of FasL during CORT-treated rat Leydig cell. It is not clear yet how NFAT is involved in CORT-induced up-regulation of FasL. The aim of the present study is to investigate the molecular mechanisms of NFAT-mediated FasL expression in CORT-treated Leydig cells.Results: Western blot analysis showed that NFAT2 expression is present in mouse Leydig tumor cell (mLTC-1). CORT-induced increase in FasL expression in mLTC-1 was ascertained by Western Blot analysis and CORT-induced increase in apoptotic frequency of mLTC-1 cells was detected by FACS with annexin-V labeling. Confocal imaging of NFAT2-GFP in mLTC-1 showed that high level of CORT stimulated NFAT translocation from the cytoplasm to the nucleus. RNA interference-mediated knockdown of NFAT2 significantly attenuated CORT-induced up-regulation of FasL expression in mLTC. These results corroborated our previous finding that NFAT2 is involved in CORT-induced FasL expression in rat Leydig cells and showed that mLTC-1 is a suitable model for investigating the mechanism of CORT-induced FasL expression. The analysis of reporter constructs revealed that the sequence between -201 and +71 of mouse FasL gene is essential for CORT-induced FasL expression. The mutation analysis demonstrated that CORT-induced FasL expression is mediated via an NFAT binding element located in the -201 to +71 region. Co-transfection studies with an NFAT2 expression vector and reporter construct containing -201 to +71 region of FasL gene showed that NFAT2 confer a strong inducible activity to the FasL promoter at its regulatory region. In addition, chromatin immunoprecipitation assay further confirmed the results of reporter gene studies by showing the specific binding of NFAT2 to the -201 to +71 region.Conclusion: In the present study, we demonstrated that NFAT2 directly stimulates transcription of FasL in high level CORT-treated mLTC-1. In conclusion, the present study provides further evidence for our finding that CORT-induced FasL expression in Leydig cells is mediated by NFAT.
- 12 June 2008
- Published by Springer Nature in BMC Cell Biology
- Vol. 9 (1) , 31
Open AccessMechanism of nuclear factor of activated T-cells mediated FasL expression in corticosterone -treated mouse Leydig tumor cells
Background: Fas and FasL is important mediators of apoptosis. We have previously reported that the stress levels of corticosterone (CORT, glucocorticoid in rat) increase expression of Fas/FasL and activate Fas/FasL signal pathway in rat Leydig cells, which consequently leads to apoptosis. Moreover, our another study showed that nuclear factor of activated T-cells (NFAT) may play a potential role in up-regulation of FasL during CORT-treated rat Leydig cell. It is not clear yet how NFAT is involved in CORT-induced up-regulation of FasL. The aim of the present study is to investigate the molecular mechanisms of NFAT-mediated FasL expression in CORT-treated Leydig cells.Results: Western blot analysis showed that NFAT2 expression is present in mouse Leydig tumor cell (mLTC-1). CORT-induced increase in FasL expression in mLTC-1 was ascertained by Western Blot analysis and CORT-induced increase in apoptotic frequency of mLTC-1 cells was detected by FACS with annexin-V labeling. Confocal imaging of NFAT2-GFP in mLTC-1 showed that high level of CORT stimulated NFAT translocation from the cytoplasm to the nucleus. RNA interference-mediated knockdown of NFAT2 significantly attenuated CORT-induced up-regulation of FasL expression in mLTC. These results corroborated our previous finding that NFAT2 is involved in CORT-induced FasL expression in rat Leydig cells and showed that mLTC-1 is a suitable model for investigating the mechanism of CORT-induced FasL expression. The analysis of reporter constructs revealed that the sequence between -201 and +71 of mouse FasL gene is essential for CORT-induced FasL expression. The mutation analysis demonstrated that CORT-induced FasL expression is mediated via an NFAT binding element located in the -201 to +71 region. Co-transfection studies with an NFAT2 expression vector and reporter construct containing -201 to +71 region of FasL gene showed that NFAT2 confer a strong inducible activity to the FasL promoter at its regulatory region. In addition, chromatin immunoprecipitation assay further confirmed the results of reporter gene studies by showing the specific binding of NFAT2 to the -201 to +71 region.Conclusion: In the present study, we demonstrated that NFAT2 directly stimulates transcription of FasL in high level CORT-treated mLTC-1. In conclusion, the present study provides further evidence for our finding that CORT-induced FasL expression in Leydig cells is mediated by NFAT.